Companies
Magnitude Biosciences Raises £1.3 Million to Scale Drug Screening in Living Worms
The Durham spinout is expanding VivoScan, an automated whole-worm screening platform. The funding supports scale, but promising worm results still need mammalian…
Insilico Wants to Build a “Longevity Vaccine.” Here’s What Actually Exists So Far
Insilico’s “Longevity Vaccines” initiative proposes programming immune cells inside the body. Related mouse studies are encouraging, but the announcement offers no programme-specific…
Moonwalk Raises $70 Million as an Epigenetics Startup Moves Toward the Clinic
Moonwalk Biosciences raised a $70 million Series B to advance adipose-targeted RNAi medicines for obesity and cardiometabolic disease. Its epigenetics-based platform is…
Korsana Closes Cyclerion Merger With $380 Million War Chest for Alzheimer’s Drug Development
Korsana completed its merger with Cyclerion and closed a $380 million financing, giving the Alzheimer’s drug developer approximately $475 million in pro-forma…
SIRT6 Gene Therapy Lowered Biological Age in Old Dogs, Genflow Says. Where Is the Data?
Genflow says its randomized, blinded trial lowered a DNA methylation age score in older beagles. The result is intriguing, but detailed numerical…
AgelessRx Says a 90-Day Longevity Trial Improved Healthspan. What Did It Actually Show?
AgelessRx reported favorable changes from an 18-person final analysis. The randomized pilot generated signals, but it did not prove slower aging or…
Brown Launches $37 Million Healthspan Alliance to Push Aging Research Toward Patients
A five-year alliance will connect Brown’s aging laboratories with its health system’s clinical-trial network. The investment builds infrastructure, not proof of a…
Temple Buys a Longevity Clinic as It Builds the Science Behind Its Health Wearable
Temple has acquired London longevity practice Longevous while building a health wearable. The deal adds clinical expertise, but the company’s scientific claims…
Sam Altman-Backed Retro Biosciences Moves Deeper Into Human Testing
Sam Altman-backed Retro Biosciences is advancing RTR242 through a Phase 1 trial in healthy volunteers. Here is what the trial can show,…
Longeveron Is Doing Another 1-for-10 Reverse Stock Split. Here’s Why That Matters.
Longeveron’s second 1-for-10 reverse split since 2024 can restore its share price mechanically. It cannot resolve runway, financing or clinical execution risk.